Logo (Novartis) 40 Pill - white round, 8mm
Generic Name: asciminib
Pill with imprint Logo (Novartis) 40 is White, Round and has been identified as Scemblix 40 mg. It is supplied by Novartis Pharmaceuticals Corporation.
Scemblix is used in the treatment of Chronic Myelogenous Leukemia and belongs to the drug class BCR-ABL tyrosine kinase inhibitors. Scemblix 40 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for Logo (Novartis) 40
Scemblix
- Generic Name
- asciminib
- Imprint
- Logo (Novartis) 40
- Strength
- 40 mg
- Color
- White
- Size
- 8.00 mm
- Shape
- Round
- Availability
- Prescription only
- Drug Class
- BCR-ABL tyrosine kinase inhibitors
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Novartis Pharmaceuticals Corporation
- National Drug Code (NDC)
- 00078-1098
See also:
Gleevec
Gleevec is targeted cancer therapy for specific types of leukemia (blood cancer), bone marrow ...
Hydrea
Hydrea is used for chronic myelogenous leukemia, head and neck cancer
Tepezza
Tepezza (teprotumumab) infusion is used for thyroid eye disease (TED). Includes Tepezza side ...
Sprycel
Sprycel is used to treat chronic myeloid leukemia and acute lymphoblastic leukemia. Learn about ...
Cytoxan
Cytoxan is used for acute lymphocytic leukemia, acute nonlymphocytic leukemia, breast cancer ...
Tasigna
Tasigna (nilotinib) is used to treat Philadelphia chromosome positive chronic myeloid leukemia ...
Bosulif
Bosulif is a kinase inhibitor that may be used to treat adults and some children aged 1 year and ...
Iclusig
Iclusig (ponatinib) used to treat a type of blood cancer called chronic myeloid leukemia (CML), or ...
More about Scemblix (asciminib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: BCR-ABL tyrosine kinase inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.